Apollomics Inc.
APLM evidence brief
What we can confirm
- Market Cap:
- $67.6M
What it means
What to watch
Prepared research question
What matters most for APLM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APLM
Apollomics Inc. is a clinical-stage biotechnology company focused on oncology therapies, with a pipeline of drug candidates targeting difficult-to-treat cancers, though it recently faced financial difficulties and discontinued its lead program.
Key risk: Financial distress
Market Cap
$67.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2024.
Tracking 4 clinical trials for Apollomics Inc..
Apollomics Inc. is a clinical-stage biotechnology company focused on oncology therapies, with a pipeline of drug candidates targeting difficult-to-treat cancers, though it recently faced financial difficulties and discontinued its lead program.
- Founded in 2015 as a spin-off from Crown Bioscience International [sec · filed 2026-04-24].
- Pipeline includes five drug candidates across 10 programs, with four in clinical stage as of 2026-04-24 [sec · filed 2026-04-24].
- Lead candidate vebreltinib (APL-101) showed positive results in over 280 patients but clinical activities were discontinued in August 2025 due to financial concerns [sec · filed 2025-10-14].
- Cash and equivalents of $9.8M as of 2024-12-31 [latest reported financials].
- Received $4.1M in PIPE investments in September 2025 and appointed a new board of directors [sec · filed 2025-10-14].
What works
- Pipeline of five drug candidates across 10 programs, with four in clinical stage, targeting multiple cancer types [sec · filed 2026-04-24].
- Over 79 active patents and patent applications, with more than 50 owned or directly filed by Apollomics [sec · filed 2025-04-03].
- Experienced management team strengthened in Q3 2025 with expertise in corporate restructuring, global clinical operations, and capital markets [sec · filed 2026-04-24].
What to weigh
- Lead program vebreltinib (APL-101) clinical activities were discontinued in August 2025 due to financial concerns, and the company sought shareholder approval to wind up business [sec · filed 2025-10-14].
- Cash and equivalents of only $9.8M as of 2024-12-31, indicating limited financial runway [latest reported financials].
- Company is a Cayman Islands holding company with no material operations of its own, relying on subsidiaries in Hong Kong and China [sec · filed 2026-04-24].
From the filings
Quoted directly from source documents.
Pipeline composition and clinical stage
“built a pipeline of five drug candidates across 10 programs that focus on oncology, of which four drug candidates are in the clinical stage”
SEC filings · April 24, 2026
Discontinuation of lead program due to financial concerns
“the Company, citing financial concerns, announced on Form 6-K (the "August 28 Announcement") that it "expected" to discontinue all clinical trial activities related to APL-101 (vebreltinib) (also known as SPARTA) and that it intended to seek shareholder approval to wind up the Company's business”
SEC filings · October 14, 2025
Recent PIPE investment and board change
“the Company announced on Form 6-K that it had received $4.1 million PIPE investments from certain investors and appointed a new board of directors”
SEC filings · October 14, 2025
Risks & what to watch (3)›
Key risks
- Financial distress — Cash of $9.8M as of 2024-12-31 is low; lead program discontinued due to financial concerns [latest reported financials] [sec · filed 2025-10-14].
- Lead program halted — Vebreltinib clinical activities discontinued; company sought shareholder approval to wind up [sec · filed 2025-10-14].
- Holding company structure — Company is a Cayman Islands holding company with no material operations, relying on subsidiaries [sec · filed 2026-04-24].
What to watch
- Outcome of shareholder vote on winding up the company, as sought in August 2025 [sec · filed 2025-10-14].
- Use of $4.1M PIPE investment and any further financing or restructuring moves [sec · filed 2025-10-14].
- Progress of remaining clinical-stage programs, if any, given financial constraints [sec · filed 2026-04-24].
Sources: SEC filings · Generated October 13, 2026 · How we verify sources →
Run Apollomics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Apollomics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$7K
| Holder | Shares | Value |
|---|---|---|
| citigroup inc | 438 | $7K |
| blackrock, inc. | 1 | $16 |
Short Interest
as of May 20, 2026- % of float
- 0.2%
- Days to cover
- 0.3
- Shares short
- 2,692
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APLM short interestFrequently asked questions
What is the AI investment thesis for Apollomics Inc.?
Apollomics Inc. is a clinical-stage biotechnology company focused on oncology therapies, with a pipeline of drug candidates targeting difficult-to-treat cancers, though it recently faced financial difficulties and discontinued its lead program.
Who is the CEO of Apollomics Inc.?
Mr. Hung-Wen Chen is the chief executive officer of Apollomics Inc. (APLM).
Where is Apollomics Inc. headquartered?
Apollomics Inc. (APLM) is headquartered in Foster City, CA, United States.
What therapeutic areas does Apollomics Inc. focus on?
Apollomics Inc. develops therapies across Oncology, Nephrology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.